Understanding Ductal Carcinoma In Situ (DCIS) diagnosis, staging, and treatment? Find clear information on DCIS, also known as Intraductal Carcinoma, including clinical documentation, medical coding, healthcare guidelines, and pathology reports. Learn about DCIS prognosis, risk factors, and current research for optimal patient care. This resource supports healthcare professionals in accurate documentation and coding related to DCIS for improved clinical workflows.
Also known as
Ductal carcinoma in situ of breast
DCIS or intraductal carcinoma, non-invasive breast cancer.
Malignant neoplasm of breast
Covers invasive breast cancers, may be used for advanced DCIS.
Personal history of malignant neoplasm of breast
For patients with a history of DCIS after completed treatment.
Follow this step-by-step guide to choose the correct ICD-10 code.
Is the DCIS of the breast?
When to use each related code
| Description |
|---|
| Breast cancer that has not spread outside milk ducts. |
| Invasive breast cancer spread to surrounding tissues. |
| Abnormal breast cells with increased risk of cancer. |
Missing or incorrect laterality (right, left, bilateral) for DCIS can impact treatment and reimbursement accuracy. CDI should query for clarity.
Miscoding DCIS as invasive carcinoma or vice versa leads to significant staging and treatment discrepancies. Careful documentation review is crucial.
Omitting the nuclear grade of DCIS (e.g., low, intermediate, high) affects prognosis and treatment. CDI must ensure accurate documentation and coding.
Q: What are the latest NCCN guidelines for managing ductal carcinoma in situ (DCIS) in patients with dense breast tissue?
A: The current NCCN guidelines for DCIS management emphasize a personalized approach considering factors like patient age, tumor grade, size, and presence of comedonecrosis, especially in patients with dense breasts where mammographic detection can be challenging. For low-grade DCIS without comedonecrosis, active surveillance with close monitoring may be an option. However, for high-grade DCIS or those with comedonecrosis, surgical excision (lumpectomy or mastectomy) with or without radiation therapy is typically recommended. The choice between lumpectomy and mastectomy depends on individual factors and patient preferences. Explore how recent advances in imaging techniques like molecular breast imaging can contribute to the diagnostic accuracy of DCIS in dense breast tissue and aid in surgical planning. Consider implementing risk assessment tools to stratify patients and guide treatment decisions.
Q: Distinguishing between DCIS and IDC relies on careful histopathological examination of breast biopsy specimens. Key features of DCIS include the confinement of malignant cells within the ductal system without invasion of the basement membrane. IDC, on the other hand, demonstrates invasion of the surrounding stroma. Immunohistochemical markers like E-cadherin can help identify the intact basement membrane in DCIS, whereas loss of E-cadherin staining may suggest invasive disease. Accurate differentiation has significant treatment implications, as DCIS is considered a non-invasive precursor lesion, while IDC requires more aggressive treatment strategies, including potential lymph node dissection and systemic therapies like chemotherapy or endocrine therapy. Learn more about the role of advanced imaging modalities, such as MRI, in differentiating between DCIS and IDC, especially when biopsy findings are inconclusive.
A:
Patient presents with concerns regarding breast changes. Physical examination revealed [describe findings, e.g., no palpable mass, no skin changes, no nipple discharge]. Mammography demonstrates [describe mammographic findings, e.g., microcalcifications in the upper outer quadrant of the right breast]. Subsequent breast biopsy confirmed the diagnosis of ductal carcinoma in situ (DCIS), also known as intraductal carcinoma. The DCIS is [describe grade, e.g., low grade, intermediate grade, high grade] and [describe characteristics, e.g., comedo type, cribriform type, solid type, papillary type]. Immunohistochemical stains are [describe results, e.g., ER positive, PR positive, HER2 negative]. The diagnosis of DCIS was discussed with the patient, including the implications for breast cancer risk. Treatment options, including surgical excision (lumpectomy), mastectomy, radiation therapy, and hormonal therapy (e.g., tamoxifen), were reviewed. Risks and benefits of each treatment option were explained, taking into account the patient's age, overall health, family history of breast cancer, and personal preferences. A sentinel lymph node biopsy will be considered. Patient will follow up for further discussion and decision regarding the treatment plan. Current procedural terminology (CPT) and International Classification of Diseases (ICD) codes will be assigned appropriately for billing and coding purposes. This documentation is for electronic health record (EHR) use and complies with relevant medical documentation guidelines.